This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
ASP is a crucial pricing metric for provider-administered drugs and is commonly used as a benchmark for physician drug reimbursement.
The relationship between ASP dynamics and changes to WAC, both publicly available, offers insight into the apparent level of price concessions for a product. This CRA Insights examines how the relationship between WAC and ASP can inform hypotheses as to the types of discounting and contracting strategies that may be employed by the pharmaceutical manufacturer.
Several pivotal topics emerged, establishing predominant themes throughout the conference. Although efficacy continues to be the fundamental basis of oncology...
However, expert evidence on economic issues is likely to become increasingly important for UPC proceedings in the near term. CRA consultants Andrew Tepperman,...
Is Going to a Private-Equity Owned Hospital Bad for Your Health? Private equity investment in health care has increased more than 20-fold—from $5 billion in...
Erin McDermott moderates the session exploring practical strategies for balancing caregiving responsibilities with professional goals. Caring for a parent,...
